Graff, J. N., Tagawa, S., Hoimes, C., Gerritsen, W., Vaishampayan, U. N., Elliott, T., … Antonarakis, E. S. (2021). 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. In Annals of Oncology (Vol. 32, pp. S383–S383). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.341

Graff, J. N., S. Tagawa, C. Hoimes, W. Gerritsen, U. N. Vaishampayan, T. Elliott, C. Hwang, et al. “61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199.” In Annals of Oncology, 32:S383–S383. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.341.

Graff JN, Tagawa S, Hoimes C, Gerritsen W, Vaishampayan UN, Elliott T, et al. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. In: Annals of Oncology. Elsevier BV; 2021. p. S383–S383.

Graff, J. N., et al. “61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S383–S383. Crossref, doi:10.1016/j.annonc.2021.08.341.

Graff JN, Tagawa S, Hoimes C, Gerritsen W, Vaishampayan UN, Elliott T, Hwang C, Tije AJT, Omlin AG, McDermott RS, De Wit R, Qiu P, Poehlein C, Kim J, Suttner L, Cristescu R, Marton MJ, Schloss C, de Bono JS, Antonarakis ES. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. Annals of Oncology. Elsevier BV; 2021. p. S383–S383.